On February 25, Baiji Shenzhou, the world's first pharmaceutical giant to achieve "a + H + n" listing, released a performance express. The performance express shows that in 2021, the company achieved an operating revenue of 7.589 billion yuan, an increase of 257.9% over the previous year; The net profit loss attributable to the owners of the parent company was 9.748 billion yuan, compared with 11.384 billion yuan in the same period last year.
The company said that during the reporting period, the company's operating revenue increased by 257.9% over the same period of the previous year, mainly due to the increase in the sales volume of the company's self-developed products and authorized products, as well as the new income from technology licensing and R & D services.
According to the announcement, in 2021, the product revenue was 4.090 billion yuan, compared with 2.120 billion yuan in the same period of last year. The growth of product revenue was mainly due to the sales growth of self-developed products and authorized products.
The cooperation income was 3.499 billion yuan, mainly from the recognition of part of the income from the cooperation advance payment of US $650 million for PD-1 antibody drug baizean obtained with Novartis in the first quarter of 2021 and the cooperation advance payment of US $300 million for tigit inhibitor ociperlimab in the fourth quarter of 2021.
By product, in 2021, the global sales of BTK inhibitor Hyatt (zebutinib capsule) totaled 1.406 billion yuan, compared with 286 million yuan in the same period of last year.
Among them, the U.S. market sales totaled 746 million yuan, compared with 126 million yuan in the same period last year, mainly from the increasing market demand in the fields of mantle cell lymphoma (MCL), Fahrenheit macroglobulinemia (WM) and marginal zone lymphoma (MZL), which continued to accelerate the growth of sales in the United States in 2021.
In China, the sales volume of Hyatt China totaled 652 million yuan, compared with 160 million yuan in the same period of last year. The growth of sales volume in the Chinese market was mainly due to the sales growth in many approved indications, including chronic lymphoblastic leukemia (CLL), MCL and WM. A new indication for WM patients of adults who have received at least one treatment in the past has been included in the national medical insurance catalogue (2021).
In addition, in 2021, the sales of baizean (tirelizumab injection) in China totaled 1.647 billion yuan, and the sales in the Chinese market totaled 1.118 billion yuan in the same period of last year. The demand for new patients brought about by the expansion of the scope of medical insurance reimbursement, the further expansion of the sales team and the increase in the number of drugs entering the hospital have continuously promoted the expansion of baizean's market penetration and market share. Baizean added three indications for first-line treatment of non squamous non-small cell lung cancer (NSCLC), first-line treatment of squamous NSCLC and second-line or third-line treatment of hepatocellular carcinoma (HCC), which were included in the national medical insurance catalogue (2021).
Continue to commercialize products in China and bring new products to the market in 2021. In 2021, baihuize (pamipali capsule), a newly launched and independently developed product, is aimed at treating patients with recurrent advanced ovarian cancer, fallopian tube cancer or primary peritoneal cancer with germline BRCA (gbrca) mutation who have previously received second-line or more chemotherapy. Baihuize has been included in the national medical insurance catalogue (2021). The national medical insurance catalogue (2021) has been officially implemented since January 1, 2022. In 2021, the newly listed authorized products include belintoximab for injection and kaizebai β Injection), savinco (rituximab for injection) and pubeshi (bevacizumab injection biological analogue). At present, the company commercializes a total of 11 products in China, of which 8 are authorized products.
The announcement shows that the company is committed to being the pioneer of China's innovative drugs to the sea, continuously promoting the globalization of self-developed drugs and improving drug accessibility. At the same time, the company accelerated the development of diversified and innovative drug pipelines by strengthening independent R & D capabilities and cooperation. Affected by the growth of the above product revenue and cooperation revenue, the total loss of the company in 2021 decreased compared with the same period of the previous year.
On December 15, 2021, Baiji Shenzhou landed on the science and innovation board, realizing the listing in the United States, Hong Kong and A. However, the share price suffered a break on the first day of listing on the science and innovation board. On February 25, the company's share price rose 4.7% to close at 123.58 yuan / share, which has fallen by more than 35% from the issue price. The latest total market value is 164.6 billion yuan.
